Nelson Watts, MD
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1740238229
Payments from drug & device makers
Across 586 payments — averaging $593.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$248K
- Radius Health, Inc.$34K
- AbbVie$28K
- Novo Nordisk$12K
- Sanofi US Services Inc.$8K
- Boehringer Ingelheim$8K
- plus $10K from 26 others
Across 1 payment — averaging $9422.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$9K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 360 | $247,696 |
| Radius Health, Inc. | 54 | $33,541 |
| AbbVie | 25 | $28,118 |
| Novo Nordisk | 19 | $11,979 |
| Sanofi US Services Inc. | 8 | $8,375 |
| Boehringer Ingelheim | 9 | $8,134 |
| Ipsen Bioscience Inc. | 1 | $6,270 |
| Ascendis Pharma Endocrinology Inc | 2 | $1,868 |
| Tandem Diabetes Care, Inc. | 13 | $436 |
| Medtronic(2 entities) | 25 | $342 |
| Lilly USA, LLC | 15 | $234 |
| Insulet Corporation | 11 | $187 |
| Shire North American Group Inc | 3 | $136 |
| Dexcom, Inc. | 7 | $128 |
| Cequr Corporation | 3 | $92 |
| BETA Bionics, Inc. | 3 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Sequel Med Tech, LLC | 3 | $53 |
| Mannkind Corporation | 3 | $50 |
| Amarin Pharma, Inc. | 2 | $37 |
| Amryt Pharma Holdings Ltd | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Bayer | 2 | $31 |
| AstraZeneca | 2 | $25 |
| Corcept Therapeutics | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
How this compares
$348,065 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Cincinnati
- Shawn PeavieCincinnati$201K
- Amanda DenneyCincinnati$183K
- Robert CohenCincinnati$136K
- Shailendra PatelCincinnati$68K
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.